Botanix Pharmaceuticals Limited (BOT.AX)

AUD 0.39

(1.3%)

Market Cap (In AUD)

708.87 Million

Revenue (In AUD)

601.82 Thousand

Net Income (In AUD)

-13.86 Million

Avg. Volume

7.37 Million

Currency
AUD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.1625-0.445
PE
-
EPS
-
Beta Value
1.867
ISIN
AU000000BOT2
CUSIP
Q1698B128
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Howie McKibbon
Employee Count
-
Website
https://www.botanixpharma.com
Ipo Date
1988-01-31
Details
Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company engages in development of novel treatments for common skin diseases and infections. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIb clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase IIb clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. The company was incorporated in 1984 and is based in Leederville, Australia.